ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Toosendanin enhances endothelial repair and prevents inflammation via E2F1 mediated LINC01089.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ReducedInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelial dysfunction represents a critical pathological process underlying various cardiovascular diseases, yet therapeutic strategies targeting endothelial repair remain limited. This study investigated whether toosendanin (TSN), a tetracyclic triterpenoid from Melia toosendan, promotes endothelial repair and suppresses inflammation through novel molecular mechanisms. Human dermal microvascular endothelial cells (HDMECs) and human umbilical vein endothelial cells (HUVECs) were treated with TSN (0-20 μM) and assessed for proliferation, inflammatory responses, and molecular changes using Cell Counting Kit-8 (CCK-8) assays, 5-ethynyl-2'-deoxyuridine (EdU) incorporation, quantitative real-time PCR (qPCR), Western blotting, enzyme-linked immunosorbent assay (ELISA), and RNA sequencing (RNA-seq) analysis. TSN significantly enhanced endothelial cell proliferation in a dose- and time-dependent manner, with maximal effects at 10-20 μM. Under inflammatory conditions, TSN markedly attenuated tumor necrosis factor-α (TNF-α)-induced upregulation of adhesion molecules (intercellular adhesion molecule-1 [ICAM-1], vascular cell adhesion molecule-1 [VCAM-1]), chemokine secretion (C-C motif chemokine ligand 2 [CCL2], and C-X-C motif chemokine ligand 1 [CXCL1]). RNA-seq analysis identified LINC01089 as the most significantly upregulated long non-coding RNA following TSN treatment. Functional studies revealed that TSN upregulates transcription factor E2F transcription factor 1 (E2F1), which directly activates LINC01089 transcription, establishing a positive feedback loop essential for both pro-proliferative and anti-inflammatory effects. LINC01089 knockdown significantly impaired TSN's beneficial effects, while overexpression rescued E2F1 knockdown phenotypes. This study provides the first evidence that TSN enhances endothelial repair and prevents inflammation through the E2F1-mediated upregulation of LINC01089, representing a novel therapeutic mechanism for treating vascular diseases characterized by endothelial dysfunction.
Indexed as
Identifiers
41533157What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.